CAI
Caris Life Sciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$25.07
−0.99%Margins
Gross margin
69.7%
EBITDA margin
17.5%
EBIT margin
15.5%
Net margin
10.6%
FCF margin
14.8%
17.8%
Return on equity
8.6%
Return on assets
14.7%
Return on invested capital
0.83x
Asset turnover
$201.4M
Cash from operations
$2.81
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026